When MWA is combined with anti-CTLA-4/PD-1 therapy, an increase in the CD8+ T-cell population may facilitate the clearance of unablated tumor cells, thereby protecting the host from tumor recurrence or neoplastic cells [50]. This evidence concerns the gene CD8A and neoplasm.